Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

Harriet L. Robinson, David C. Montefiori, R. Paul Johnson, +14

Nature Medicine

VaccinationHuman RetrovirusImmunologyAntiviral ResponseVirology +9

Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen.

L P Chen, Elaine K. Thomas, Shiu-Lok Hu, +2

Proceedings of the National Academy of Sciences

ImmunologyImmunoeditingPathologyImmunotherapyAnti-hpv Vaccines +15

Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival

Andrew J. Watson, Jane Ranchalis, Bruce Travis, +5

Journal of Virology

Plasma ViremiaDiagnostic VirologyViral PersistenceViral DiagnosticsHuman Retrovirus +12

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

Elizabeth Cooney, M J McElrath, Lawrence Corey, +7

Proceedings of the National Academy of Sciences

TRIMCyp expression in Old World primates <i>Macaca nemestrina</i> and <i>Macaca fascicularis</i>

Greg Brennan, Yury Kozyrev, Shiu-Lok Hu

Proceedings of the National Academy of Sciences

PrimatologyReverse GeneticsComparative GenomicsGeneticsTotal Rna +18

Removal of a Single N-Linked Glycan in Human Immunodeficiency Virus Type 1 gp120 Results in an Enhanced Ability To Induce Neutralizing Antibody Responses

Yun Li, Bradley Cleveland, I. N. Klots, +6

Journal of Virology

ImmunologyAntiviral DrugViral Structural ProteinImmunotherapyEnvelope Protein +15

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile

Nancy L. Haigwood, Andrew J. Watson, William F. Sutton, +9

Immunology Letters

Autoimmune DiseaseHumoral ResponseImmunologyTherapeutic EfficacyAutoimmunity +8

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

Todd Bradley, Justin Pollara, Sampa Santra, +33

Nature Communications

Vaccination of Vaccinia-Naive Adults with Human Immunodeficiency Virus Type 1 gp160 Recombinant Vaccinia Virus in a Blinded, Controlled, Randomized Clinical Trial

Bria Graham, Robert B. Belshe, M L Clements, +17

The Journal of Infectious Diseases

Randomized Clinical TrialImmunologyPeak ResponseVaccine TargetHivac-1e Recipients +15

Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16

Lieping Chen, M T Mizuno, Mitra C. Singhal, +4

The Journal of Immunology